Zobrazeno 1 - 7
of 7
pro vyhledávání: '"L. Maciejko"'
Autor:
L. Maciejko, V. Palacios, K. Van Abel, T. Halfdanarson, A.V. Chintakuntlawar, P.W. McGarrah, K. Tasche
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:e52-e53
Autor:
Hans Gertje, Padhma Radhakrishnan, Aaron Goldman, L Maciejko, Manjusha Biswas, Saravanan Thiyagarajan, Mark Lawson, Gb K, Allen Thayakumar, Biswanath Majumder, Baraneedharan Ulaganathan, Munisha Smalley, Basavaraja U. Shanthappa, Kodaganur S. Gopinath
Publikováno v:
Cancer Research. 78:P5-11
Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised o
Autor:
Baraneedharan Ulaganathan, L Maciejko, S. P. Somashekhar, Neyaz Alam, Munisha Smalley, J Ganesh, Basavaraja U. Shanthappa, Nabendu Murmu, Mark Lawson, Allen Thayakumar, Hans Gertje, Aaron Goldman
Publikováno v:
Cancer Research. 79:P6-07
Background: Outgrowth of new blood vessels (neovascularization) allows tumors to supply themselves with oxygen and nutrients, and to rapidly metastasize throughout the body. Triple negative breast cancer (TNBC) is particularly susceptible to neovascu
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches
Publikováno v:
Journal of molecular biomarkers & diagnosis
Purpose of review: The vision and strategy for the 21st century treatment of cancer calls for a personalized approach in which therapy selection is designed for each individual patient. While genomics has led the field of personalized cancer medicine
Autor:
Aaron Goldman, Mark Lawson, Munisha Smalley, Hans Gertje, P. Radhakrishnan, Govind Babu, B. Majumder, L Maciejko, Baraneedharan Ulaganathan, Kodaganur S. Gopinath, Allen Thayakumar, M. Biswas, S. Thiyagarajan, Basavaraja U. Shanthappa
Publikováno v:
Annals of Oncology. 28:xi9
Autor:
Aaron Goldman, Saravanan Thiyagarajan, Hans Gertje, Baraneedharan Ulaganathan, Biswanath Majumder, Manjusha Biswas, Debapriya G. Mehrotra, Padhma Radhakrishnan, Basavaraja U. Shanthappa, L Maciejko, Allen Thaya Kumar
Publikováno v:
Journal of Clinical Oncology. 35:e20035-e20035
e20035 Background: Immunotherapy has emerged as a powerful treatment paradigm wherein therapies primarily target immune components. For example, blockade of PD-1 and PD-L1 offers effective treatment options for patients with aggressive tumors such as
Autor:
Maciejko L; Integrative Immuno-Oncology Center, Mitra Biotech Woburn, MA 01801, USA., Smalley M; Integrative Immuno-Oncology Center, Mitra Biotech Woburn, MA 01801, USA., Goldman A; Integrative Immuno-Oncology Center, Mitra Biotech Woburn, MA 01801, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.; Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Publikováno v:
Journal of molecular biomarkers & diagnosis [J Mol Biomark Diagn] 2017 Sep; Vol. 8 (5). Date of Electronic Publication: 2017 Jun 28.